logo.jpg
Addex Reports Q3 2022 Financial Results and Provides Corporate Update
November 11, 2022 01:00 ET | Addex Therapeutics
CHF10.4M ($10.4M) of cash and cash equivalents at September 30, 2022Janssen led ADX71149 Phase 2 study in epilepsy on track to complete part 1 in Q1 2023 Ad Hoc Announcement Pursuant to Art. 53 LR ...
logo.jpg
Addex Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 11, 2022
November 03, 2022 02:00 ET | Addex Therapeutics
Geneva, Switzerland, November 3, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today...
logo.jpg
Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
November 03, 2022 02:00 ET | Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, November 3, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
logo.jpg
Addex Increases Issued Share Capital to Create Treasury Shares
November 01, 2022 02:00 ET | Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, November 1, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
logo.jpg
Addex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader Investment Conference
September 20, 2022 01:00 ET | Addex Therapeutics
Geneva, Switzerland, September 20, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
logo.jpg
Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update
August 18, 2022 01:00 ET | Addex Therapeutics
CHF8.8M ($9.3M) of cash and cash equivalents at June 30, 2022CHF4.6M equity financing in July extends cash runway into Q2 2023Janssen led ADX71149 Phase 2 study in epilepsy expected to report data in...
logo.jpg
Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders
August 15, 2022 01:00 ET | Addex Therapeutics
Addex to Receive CHF850,000 ($900,000) of Additional Funding; Addex’s Reserved Indications Expanded to include Chronic Cough Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August...
logo.jpg
Addex Therapeutics to Report Half-Year 2022 Financial Results and Host Conference Call on August 18, 2022
August 12, 2022 01:00 ET | Addex Therapeutics
Geneva, Switzerland, August 12, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today...
logo.jpg
Addex Completes $4.2 Million Equity Financing
July 26, 2022 16:00 ET | Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 26, 2022 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
logo.jpg
Addex Raises $4.2 million in Equity Financing
July 22, 2022 01:00 ET | Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2022 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...